Skip to main content

Advertisement

Table 1 Patient characteristics

From: Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Cohort Case Age/gender Diagnosis Disease stage ECOG/PS Prior treatment Combined treatment (chemotherapy) NK cell administration
1 1 57/M Rectal cancer Recurrent 1 Surgery, chemotherapy None Excluded from triala
2 74/F Rectal cancer Recurrent 0 Surgery, chemotherapy S-1 Excluded from triala
3 61/M Esophageal cancer Metastatic 2 Chemotherapy, radiation therapy None Complete
4 62/M Gastric cancer Recurrent 2 Surgery, chemotherapy S-1 Incomplete (2 times)
5 72/M Esophageal cancer Recurrent 0 Surgery, chemotherapy None Complete
6 73/M Colon cancer Recurrent 0 Surgery, chemotherapy None Complete
7 66/M Gastric cancer Metastatic 0 Chemotherapy None Complete
2 8 62/M Esophageal cancer Recurrent 0 Surgery, chemotherapy, radiation therapy None Complete
9 65/M Colon cancer Metastatic 0 Chemotherapy S-1 Complete
10 67/M Esophageal cancer Metastatic 2 Chemotherapy, radiation therapy None Incomplete (2 times)
11 69/M Gastric cancer Metastatic 0 Chemotherapy None Complete
3 12 60/M Colon cancer Recurrent 0 Surgery, chemotherapy None Complete
13 78/F Rectal cancer Recurrent 0 Surgery, chemotherapy None Complete
14 48/F Rectal cancer Recurrent 0 Surgery, chemotherapy, radiation therapy None Complete
  1. ECOG Eastern Coorperative Oncology Group, PS performance status
  2. aTwo patients were excluded from trial because the purity (no. 1) or the number (no. 2) of expanded cells didn’t exceed eligible value